Introduction
Nearly 50 years have passed since Thomas et al. 1 reported one of the first successful matched-related donor bone marrow transplant (BMT) procedures that resulted in longterm survival in a leukemic patient. The year 1968 marked a major landmark in BMT in treating nonmalignant diseases with a successful allogeneic transplantation performed in an infant with X-linked lymphopenic immune deficiency and in another with Wiskott-Aldrich syndrome. 2 These successes were followed by stepwise advances making this approach a life-saving art for hematologic malignancies, inherited metabolic, immune and red cell disorders as well as marrow failure states. The use of peripheral blood stem cell transplants (PBSCT) in place of bone marrow cells have subsequently gained increasing popularity after initial introduction in the 1980s. 3 Recently, umbilical cord blood (UCB) has emerged as an alternative source of hematopoietic stem cells for transplantation. 4, 5 Despite advances in performing hematopoietic stem cell transplant (SCT) procedures, this life-saving art continues to be associated with visceral organ injury, systemic infection and graft-versus-host disease (GVHD). These complications, alone or in combination, may result in mortality. When these or any major complications arise, clinicians often turn to the resources afforded by the modern intensive care unit (ICU). Such units are staffed with highly specialized clinicians, nurses and ancillary personnel who employ a multidisciplinary approach that often improve the clinical course and outcome in this critically ill patient population.
A significant number of patients who undergo SCT suffer complications that require ICU management. The most frequent reasons the SCT patient is transferred or directly admitted to the ICU are outlined in Table 1 . As expected, the conditions most commonly responsible for ICU transfer involve failure of respiratory, cardiac and neurologic systems, gastrointestinal bleeding and infections with associated sepsis syndrome. These complications can be addressed and potentially corrected using the monitoring facilities and highly trained personnel present in the contemporary ICU. Multiple transplant centers reporting the incidence of ICU admission among their BMT and PBSCT recipients have outlined a number of factors that may define prognosis in this group of patients. An extensive review of English language literature reveals the many variables associated with increased patient morbidity and mortality after transfer to the ICU, the most common of which are respiratory failure requiring intubation, multiorgan system failure (MOSF), hemodynamic instability or shock and presumed or documented infection ( Table 2) . The majority of reports described BMT patients admitted to the ICU while more recent communications addressed those subjects who have undergone PBSCT. Recently, publications have appeared analyzing pediatric UCBT recipients admitted to the ICU. To our knowledge, as yet there have been no reports describing adult UCBT recipients. Our assessment of this literature leads one to suggest that as of circa 1998 SCT recipients are less likely to require ICU support, and the outcome for those requiring such care has improved. Herein we review these supporting data, evaluate the prognostic factors and address issues that may lead to further improvement in patient outcome.
Methods
Pertinent English language publications were identified by searching PubMed using the keywords 'intensive care unit,' 'bone marrow transplantation,' 'hematopoietic stem cell transplantation', 'allogeneic', 'autologous' and 'umbilical cord blood.' Our search encompassed the years 1980 through 2005. Additional publications were identified using the reference lists of relevant papers. For purposes of comparing various studies, which defined survival in many ways, survival to hospital discharge was considered.
Selection biases
The decision to transfer a patient to an ICU is quite complex and the resultant reported or desired outcome/ survival statistics must be interpreted within the larger scope of the much larger number of patients eligible for transplant. Clearly, some patients are not considered SCT candidates while others simply are not referred for the procedure and some decline this option. Further, once a transplant is performed, many subjects fare well and an ICU is not needed whereas some patients' clinical course may deteriorate rapidly and not undergo ICU transfer if the insult is catastrophic. Finally, in the era of an increasingly informed patient population, some patients may choose not to go to an ICU regardless of the nature of their clinical course or acute deterioration. Such decisions, the result of discussions between the patient, family and health care team, now are routine before the SCT procedure and usually occur prior to a patient's clinical deterioration. This 'decision tree' clearly will affect the likelihood of a transplant patient undergoing transfer to and dying within an ICU. Given such limitations, we have chosen in this review to address factors that may influence ICU transfer and the advances and strategies that may improve SCT patient outcome within the ICU.
The adult SCT patient Data for adult patients who have undergone BMT and PBSCT and required ICU transfer or admission are reviewed. The time period 1980-1998 (Table 3) encompasses patients undergoing BMT vs the interval 1998 to the present (Table 4) , in which studies in this era began analyzing patients who underwent PBSCT. As can be seen from our study summaries (Tables 3 and 4) , a number of reports used intubation and mechanical ventilation as a surrogate for ICU transfer in situations where transplant units encompass an ICU-like setting. The studies which only address transplant patients requiring mechanical ventilation, however, likely underestimate the true need for the ICU in their population since there may be patients who suffer other complications such as hemodynamic instability from sepsis and gastrointestinal bleeding who do not necessarily require mechanical ventilation. As a result, wherever possible, we separate these studies from those which consider the entire population requiring intensive care in our tabular summaries (Tables 3, 4 and 5) . Table 1 The most frequent reasons for hematopoietic stem cell transplant recipients to experience ICU admission Respiratory failure and/or mechanical ventilation 6, 8, 9, 11, 12, 14, 16, 17, 18, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41 Sepsis 6, 9, 11, 12, 16, 17, 18, 20, 22, 26, 27, 29, 30, 31, 33, 34, 37, 38 Cardiac dysfunction including arrhythmia, pericardial effusion, myocardial infarction and cardiac arrest 8, 11, 12, 16, 17, 18, 20, 26, 27, 29, 30, 31, 33, 34, 38, 41 Neurologic deterioration 6, 11, 12, 17, 20, 26, 27, 29, 31, 32, 33, 34, 37, 38, 39, 41 Pneumonia 12, 18, 21, 29, 35, 36, 40 Diffuse alveolar hemorrhage 12, 18, 21, 29, 36 Acute respiratory distress syndrome 12, 18, 28, 35 Gastrointestinal bleeding 8, 11, 16, 17, 26 Table 2 Variables associated with increased hematopoietic stem cell transplant patient mortality after ICU transfer Intubation and mechanical ventilation 6, 8, 9, 11, 12, 13, 16, 17, 18, 19, 20, 21, 24, 26, 27, 28, 29, 32, 34, 36, 37, 39, 40, 41 Multiorgan system failure 6, 13, 23, 24, 25, 26, 27, 29, 32, 34, 35, 36, 37, 38, 40 Hemodynamic instability/shock 6, 9, 11, 15, 16, 20, 25, 26 Presumed or documented infection 6, 17, 20, 26, 31, 37, 40 High serum lactate concentration on ICU admission 27 Graft-versus-host disease 15, 21, 26, 29, 38 Hyperilirubinemia/hepatic failure 16, 25, 39 Gastrointestinal bleeding/macroscopic hemorrhage 17, 41 Higher APACHE and O-PRISM score 11, 16, 25, 26, 40, 41 Increased ICU length of stay 6, 8, 11, 12 Allogeneic transplant 17, 19, 40 Time interval (prolonged) between transplant and ICU transfer 9, 12, 17 Increased patient age 7, 12 Stem cell transplant and intensive care unit N Naeem et al Table 3 Selected summary characteristics for adult hematopoietic stem cell transplant patients admitted to the ICU from 1988 to 1998 The adult BMT patient Rubenfeld and Crawford 13 in 1996 presented the largest patient dataset generated between 1980 and 1992 comparing all adult BMT patients with those patients who required mechanical ventilation. A total of 3635 patients received a first BMT with 909 (25%) requiring ICU transfer and mechanical ventilation; 53 (6.1%) survived for more than 30 days after extubation. The authors compared postmechanical ventilation survivors to 106 randomly selected controls from the nonsurvivor population for factors predicting outcome. 13 Their analysis revealed that increased mortality was associated with worsening MOSF; no patient with lung injury in conjunction with either hepatic and renal failure or hemodynamic instability survived. Unfortunately, these authors' analyses only included those patients who required mechanical ventilation, excluding those patients who had respiratory, renal and hepatic dysfunction who may have had an increased mortality despite the absence of need for instituting mechanical ventilatory support. Another limitation of their study 13 would appear to arise with the definitions of lung injury and hepatic and renal failure used by these authors as they were not based on stringent and currently accepted criteria for these conditions. The definition of hepatic failure was stated to be a total serum bilirubin concentration greater than 4 mg/dl though the authors did not take into account the presence of hepatic encephalopathy. Similarly, renal failure was defined as a serum creatinine concentration greater than 2 mg/dl in the absence of considering baseline renal function. Finally, the use of the fraction of inspired oxygen concentration greater than 0.6 or a positive end-expiratory pressure greater than 5 cm as reflective of substantial lung injury without accounting for the ratio of the oxygen tension in the blood to the fraction of inspired oxygen seems an insensitive determination for quantifying lung dysfunction. Despite these limitations, the data of Rubenfeld et al. 13 were derived from such a large patient database that provided important insight into the outcome characteristics of adult BMT patients transferred to the ICU (see below).
Other studies of BMT patients requiring ICU care have noted various factors related to prognosis including increasing age, ICU length of stay of greater than 10 days, the need for mechanical ventilation for more than 4 to 14 days, and APACHE scores greater than 29-45. [6] [7] [8] [9] [10] [11] [12] [13] 16, 18 All of these studies, however, comprise patient populations significantly smaller than those presented in the report by Rubenfeld et al. 13 with variable and different criteria used for defining various organ failures. These important limitations unfortunately detract from the conclusions that can be drawn pooling the published experience from these reports. In these descriptions comprised predominantly of patients undergoing BMT for hematologic malignancy (Table 3) , 19-44% of SCT patients required ICU transfer of which only 12-23% survived to hospital discharge. In the same series of reports focusing only on the mechanically ventilated patients, 12-29% of patients required this intervention of which only 4-6% survived to hospital discharge or beyond. 7, 10, 13 The adult PBSCT patient Since 1998, several publications have emerged analyzing patient data describing PBSCT patients who require ICU care. Price et al. 17 identified 71 PBSCT and 44 BMT recipients, who required ICU care over a 19-month period (Table 4) . The overall mortality rate in this study was 54%, which increases markedly to 81% for those patients requiring intubation. The variables associated with increased mortality in the series of Price et al. 17 included intubation and mechanical ventilation, allogeneic transplant, longer elapsed time between transplant and ICU transfer, presumed or documented infection, tachycardia, tachypnea, hyperbilirubinemia and concurrent gastrointestinal bleeding. Soubani et al. 27 reported the largest and most recent study of PBSCT patients requiring ICU care. During a 3.5-year period encompassing the period 1998-2001, 745 patients underwent PBST at their center. Sixty-one percent of their patients were transplanted for hematologic malignancies representing a much lower percentage compared to the series of Rubenfeld et al.
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Most importantly, only 85 (11.4%) of patients in the Soubani et al. series 27 required ICU admission, consistent with the expectation of enhanced tolerability of PBSCT. The most frequent reasons for ICU admission in these 85 patients were respiratory failure, sepsis and cardiac dysfunction as manifest by arrhythmia, pericardial effusion, myocardial infarction, cardiac arrest, or combinations thereof. Fifty-one of these patients (60%) required intubation and mechanical ventilation during their ICU stay. Fifty-five patients (65%) had one or more organ system failure during their ICU stay with an associated ICU mortality of 28%. Factors predicting ICU mortality were a high serum lactate concentration on ICU admission, the need for mechanical ventilation and the presence of more than two organ system failures during the ICU stay. Fiftytwo of 85 (61%) patients, however, were discharged from the ICU, of which 19 (35%) had been intubated. Thirty-five patients (41%) ultimately were discharged from the hospital, 10 (20%) of whom had been intubated. Twenty one (28%) patients were alive at 6 months although most deaths, 22 of 33 (67%) occurred in the ICU after withdrawal of life support measures.
Limitations of the published experiences: adults
Despite a wide variability in ICU outcomes over both study periods, a comparison of pre-1998 studies to those communications after 1998 reveals a lower percentage of transplant patients admitted to the ICU over time, from 19-44% (Table 3 ) vs 11-22% (Table 4) . These results, however, are confounded by the fact that several studies did not report their data to enable calculation of the percentage of all transplant patients during the study period who required intensive care. 17, 19, 26 Most trials also did not address the issue of patient selection bias, that is, which patients were transferred and which were not sent to an ICU. Furthermore, the rate of patients requiring mechanical ventilation in those studies decreased from 12-29 to 6-10%. The lower ICU transfer rates and mechanical ventilation rates in studies published after 1998 also are difficult to interpret since all were single-center, retroStem cell transplant and intensive care unit N Naeem et al spective reviews employing criteria and threshold variables for ICU transfer and for mechanical ventilation that vary greatly among different centers. Nevertheless, these data reflect an overall trend toward improved adult SCT patient survival to hospital discharge over time from 12-23% in the pre-1998 period (Table 3) to 30-61% in the post-1998 period (Table 4) . For those analyses of solely mechanically ventilated patients, the survival to hospital discharge increased from 4 to 6% in the pre-1998 period to 18-26% post-1998. Despite this encouraging trend, the mortality from mechanical ventilation remained significantly higher than the mortality from all causes of ICU admission irregardless of the timeframe of the SCT procedure.
In contrast to a 'time period effect', we undertook a careful review of various patient series examining data for PBSCT recipients. Unfortunately, the majority of publications did not consistently identify pre-ICU admission clinical characteristics as important predictors of outcome. Several groups 16, 17, 26, 40 identified graft source, presence of GVHD and time of transplant to ICU admission as important predictors of poor outcome, yet such variables were not predictive in the largest report communicated by Soubani et al. 27 Interpretation of these data are confounded, however, by the fact that in two of these studies the results were drawn from data combining PBSCT and BMT recipients. 17, 26 Further, the conclusions in another trial were based on data from a very small sample size. 40 Although the report from Soubani et al. 27 included a total of 745 patients, the data interpretation is limited by the retrospective, single-center nature of their series combined with the small sample size of only 85 patients who were treated in the ICU.
The pediatric BMT and PBSCT patient Table 5 summarizes the pertinent patient demographics and outcome variables of investigations examining pediatric transplant patients treated in an ICU in the course of a SCT for which the year 2000 marks the first study which included PBSCT patients. 35 Prior to 2000 the rates of ICU transfer for pediatric SCT recipients ranged from 11 to 18% compared to the post-2000 experience in which ICU admission rates climbed to 16-29%. The rates of mechanical ventilation in those studies were 7-23% in the pre-2000 period yet no studies after 2000 reported such data. Further, no post-2000 studies reported survival to hospital discharge. On the other hand, survival to hospital discharge in mechanically ventilated patients improved from 9 to 11% pre-2000 to 28% in one study describing their experience after 2000. 39 Factors associated with poor prognosis in pediatric SCT patients admitted to the ICU are similar to what has been described for adult patients (see above, Tables 3 and 4 ) and include the presence of respiratory failure, increased duration of mechanical ventilation, MOSF, need for renal replacement therapy (hemodialysis, ultrafiltration, or the combination), hepatic toxicity, neurologic deterioration, gross hemorrhage, the presence of GVHD and a high O-PRISM score. The acronym stands for the oncological pediatric risk of mortality scale that is a well-recognized scoring system used in the pediatric oncology patient.
The pediatric UCBT patient Three reports have described ICU transfer in the pediatric UCBT recipient, 36, 39, 41 although two provide very limited information on a small number of patients. 36 , 41 Hagen et al. 39 described the clinical course for 98 ICU admissions over a 9-year period; 52 of their subjects received an UCBT and 34 underwent BMT. All 98 of their patients required mechanical ventilation. Forty-one percent of patients survived and were discharged from the ICU whereas 28% survived to hospital discharge. Overall survival at 2 years after transplant in this series was 20%. The investigators compared outcomes between BMT and UCBT recipients and noted no statistical differences in discharge from the ICU (37% UCBT vs 47% BMT) and hospital discharge (47% UCBT vs 32% BMT). Interestingly, UCBT patients had a significantly longer duration of mechanical ventilation than BMT patients (18.2 vs 9.1 days, Po0.05). For both patient groups, factors that predicted mortality were a higher grade of hepatic injury, intubation as a result of respiratory failure and sepsis and the use of high-frequency oscillatory ventilation. This latter variable likely was a surrogate for respiratory failure, similar to the association of intubation and mortality. At the time of this writing, we are unaware of any published studies in adult patients receiving UCBT and requiring ICU support.
Improvement in patient outcomes over time
Analyses of survival to hospital discharge for SCT patients who require ICU transfer reveal clear improvement in their outcome with each passing year (see above data). This result can be attributed to evolutionary improvements in both transplant-specific factors as well as contemporary ICU management strategies. Some of the more common strategies and variables responsible for the continued, evolving improvement in SCT patient outcome after ICU admission/transfer are outlined in Table 6 . Unfortunately, the true impact of these factors, alone or in combination, is not readily apparent when considering that one cannot discount the effect of patient selection bias in determining outcome as a futile clinical situation may obviate the need for ICU transfer. Under such circumstances, a patient will not be transferred nor expire in an ICU and would bias the analysis toward a better patient outcome, that is a 'Will Rogers phenomenon'. 42 One retrospective and one recent prospective study concluded that patient selection contributed to improved ICU mortality. 43, 44 Nevertheless, a number of variables we outlined in Table 6 have enhanced patient outcome after implementation of contemporary, aggressive, multimodal SCT therapies.
The increasing use of blood rather than marrow as the source of hematopoietic stem cells is a major therapeutic advance resulting in faster hematopoietic and immunologic reconstitution resulting in decreases in infections and its consequences. Support for this finding is reflected by a study in non-Hodgkin's lymphoma patients receiving either autologous PBSCT or autologous BMT. 45 PBSCT recipients had a more rapid reconstitution of NK and T cell numbers and function as compared to those given BM grafts. These effects may contribute to an improved clinical outcome and facilitate adjuvant immunotherapy after Stem cell transplant and intensive care unit N Naeem et al transplantation.
A recent meta-analysis using data from nine randomized trials enrolling 1111 adult patients showed that PBSCT compared to BMT resulted in faster neutrophil and platelet engraftment. 46 Although associated with an increased risk of extensive chronic GVHD, PBSCT also was associated with a significant decrease in relapse (21 vs 27% at 3 years) in both late-stage and early-stage-disease patients. Nonrelapse mortality was not different between PBSCT and BMT groups. Statistically significant overall and disease-free survival were improved only in late-stage disease patients.
Another important transplant-specific factor affecting improved outcome is the evolution to less toxic preparative regimens as part of the SCT procedure. The cohort study of Williams et al. 47 analyzing five different doses of once-daily administration of i.v. busulfan in combination with highdose cyclophosphamide as preparative therapy for SCT found less toxicity with lower dose regimens of busulfan. 47 Hepatic veno-occlusive disease (VOD) is a well-recognized forboding complication of the SCT procedure that can result in fatal visceral organ toxicity. Corbacioglu et al. 48 noted that 34 of 45 (76%) pediatric SCT patients so affected achieved a complete response to defibrotide, a polydeoxyribonucleotide with aptameric activity on endothelium. In the subgroup with severe hepatic VOD, 50% achieved a complete response and a long-term survival rate of 36%. 48 Richardson et al. 49 administered defibrotide 5-60 mg/kg/day for a median of 15 days to 88 adult and pediatric SCT recipients for treatment of hepatic VOD. No significant defibrotide-induced toxicity was noted and complete resolution of hepatic VOD was observed in 36%, with a 35% survival at 100 days, a vast improvement compared to previous therapeutic interventions.
Other transplant-specific factors that may have lead to improvement in outcome after ICU transfer have been the use of hematopoietic growth factors after SCT and effective yet less toxic antimicrobial therapies that can be utilized earlier in the course of transplant including nonaminoglycoside-containing antibacterial regimens, the lipid-based amphotericin preparations and the newer triazoles for systemic fungal infections. Strategies employing preemptive treatments such as anticytomegalovirus therapy and the use of improved blood component product transfusions such as leukocyte-filtered red blood cell and platelet concentrate transfusions as well as cytokine-mobilized therapeutic granulocyte transfusions appear to be associated with significant improvements in patient morbidity and mortality. Finally, more judicious patient selection for transplantation procedures also appears to have lowered the risk of treatment-related mortality by eliminating many high-risk individuals. Alternatively, many such patients with comorbid illnesses now can be offered reduced-intensity conditioning rather than myeloablative therapy. 50 Progress in ICU management parallels the improved outcome of SCT patients. Lung protective strategies have been implemented successfully for patients with acute lung injury (ALI) and acute respiratory distress syndrome (ARDS). In a landmark study 51 conducted in patients with ALI or ARDS, 429 subjects receiving mechanical ventilation using traditional tidal volumes of 12 ml/kg (predicted for body weight) and plateau pressures of 50 cm or less were compared to 432 patients receiving ventilation using much lower initial tidal volumes of 6 ml/kg with plateau pressures maintained at 30 cm or less. Those subjects treated using a lower tidal volume experienced a significant decrease in mortality (39.8-31%, P ¼ 0.007) and number of days on the ventilator (11-10 days, P ¼ 0.007). Although BMT and PBSCT patients were excluded from study, the mortality decrease was consistent across other disease and modality categories, including pneumonia, sepsis, aspiration, trauma and multiple transfusions. These data suggest that use of lower tidal volumes during mechanical ventilation for SCT patients who develop ALI or ARDS may improve mortality and patient outcome. This maneuver could have considerable impact as respiratory failure requiring mechanical ventilation has consistently proven to be a strong predictor of mortality across all time periods among BMT, PBSCT and UCBT patients (Tables 1, 3 -5) . Other evolving strategies to address lung injury include the use of new pharmacologic agents. A recent pilot study at the University of Michigan employing etanercept (soluble TNF-receptor antagonist) plus corticosteroid for the Stem cell transplant and intensive care unit N Naeem et al treatment of idiopathic pneumonia syndrome after allogeneic transplantation led to higher survival at 56 days after transplant (60 vs 26%) when compared to historic controls given corticosteroid alone (G Yanik, personnal communication 52 ). The use of noninvasive positive pressure ventilation is an intervention, which also has been shown to improve outcomes in patients with hematologic malignancies and respiratory failure. The observed outcome most likely is a result of avoiding the complications of endotracheal intubation such as alveolar barotrauma and ventilatorassociated pneumonia. Azoulay et al. 53 reported that early initiation of noninvasive ventilation (NIV) decreased the likelihood of intubation and subsequently improved overall survival in cancer patients. A prospective, randomized trial of 52 immunosuppressed patients, the majority of which had hematologic malignancies and neutropenia with pulmonary infiltrates, fever and acute hypoxemic respiratory failure compared the use of intermittent NIV with standard treatment involving supplemental oxygen and no ventilatory support. Fewer patients in the NIV group compared to the standard-treatment group required endotracheal intubation (N ¼ 12 vs 20; P ¼ 0.03), had serious complications (N ¼ 13 vs 21; P ¼ 0.02), died in the ICU (N ¼ 10 vs 18; P ¼ 0.03), or died in the hospital (N ¼ 13 vs 21; P ¼ 0.02). 54 An additional recent treatment strategy gaining acceptance is the use of early goal-directed therapy (EGDT) in the treatment of patients with severe sepsis and septic shock, which are serious complications that affect 8-23% of SCT patients requiring ICU treatment (see Tables 3-5) . This definitive resuscitation strategy is designed to achieve a balance between systemic oxygen delivery and oxygen demand in order to reduce mortality. Clinicians utilize goal-oriented manipulation of cardiac preload, afterload, and contractility in the treatment of clinically ill patients. One study 55 conducted in an emergency department setting in patients with severe sepsis and septic shock compared standard therapy in 133 patients (monitoring of central venous pressure, mean artial pressure and urine output) vs EGDT in 130 patients. The EGDT approach significantly reduced mortality from sepsis and septic shock from 46.5 to 30.5% (P ¼ 0.009). The potential benefits of using EGDT in SCT patients will await successful design and implementation of prospective clinical trials.
Decision to admit/transfer a patient for ICU care The decision to transfer SCT patients to the ICU often has been a difficult and even controversial one. [56] [57] [58] [59] [60] [61] [62] [63] [64] On the one hand, ICU personnel have often viewed transfer as oncologists 'passing the buck' or avoidance of delivering bad news to patients and families when further treatment became futile. On the other, oncologists have viewed such concerns as overly pessimistic and based on bias rather than clinical evidence. 56 Further, one study reported that physician education intervention did not result in a change in utilization of medical ICU resources by these patients. 65 The publication of outcomes data in the last decade and better communication between oncologist, ICU staff, patients and families may have resulted in better triage decisions regarding ICU transfer. Specifically, patients with a better chance of recovery may be transferred to the ICU more often and those with little chance may be allowed to die in less invasive settings. How much such events have contributed to the data we have reviewed indicating better outcomes overall or SCT patients transferred to ICU is not clear from the publications we have reviewed. Further studies should attempt to illuminate the import of this contribution. In the meantime, good communication and evidence-based decision making are essential.
Unresolved issues and areas for future research Despite our current experience with and knowledge of SCT and its positive and negative results, problematic areas persist (Table 7) . In our opinion, important issues specific to the transplant process that represent areas for further research involve investigation of ways to minimize the development of critical illness, including determination of the 'ideal' conditioning regimen, whether nonablative chemotherapy is preferable over myeloablative conditioning, the optimal stem cell source including the use of UCBT vs PBSCT vs BMT, the use of T-cell replete vs T-cell depleted stem cell sources and many others.
Traditional prognostic scoring systems such as the APACHE in adults and PRISM in pediatric patients have been criticized for having limited value in predicting the mortality of hematopoietic SCT patients. Several investigators have reported other systems for assessing organ dysfunction in the ICU but have not validated these approaches in the SCT patient or in a multicenter Table 7 Unresolved issues and areas for future research in the management of critically ill hematopoietic stem cell transplant patients
What are the ideal transplant conditioning regimens? When should a myeloablative versus a non-ablative regimen be considered? What is the optimal stem cell source for matched-related transplant recipients? For example, mobilized blood versus marrow, T-cell replete versus T-cell depleted What is the optimal alternative donor stem cell source? For example, umbilical cord blood (single, multiple units) versus unrelated adult marrow or blood, G-CSF-stimulated bone marrow Modification of the APACHE scoring system for the stem cell transplant recipient That is, add grade of GVHD as with O-PRISM score in pediatric transplant patients Improvements in therapies to treat multisystem organ failure That is, use of activated protein C to treat severe sepsis and septic shock Are stem cell transplant inpatient units equipped to provide ICU therapies (mechanical ventilation, vasopressor medications, etc) superior to separate ICUs? Are combinations of ICU resource utilization a predictor of mortality? Does initial multispecialist management (infectious disease, pulmonary medicine, nephrology and critical care) improve patient outcome? Develop prospective multicenter rather than single center trials to avoid retrospective data reporting and reduce/delete institutional effects and biases
Stem cell transplant and intensive care unit N Naeem et al setting. 66, 67 One study of 28 pediatric PBST patients requiring ICU found that the traditional PRISM score was not prognostically significant underscoring the need for modifying scores to include variables more specific to the SCT process including severity of GVHD, C-reactive protein blood concentration and the presence of macroscopic bleeding. Schneider et al. 35 began this tailoring process with the new oncologic PRISM score (O-PRISM), which has correlated significantly with the risk of ICU mortality in pediatric patients. 35 The APACHE scoring system similarly could be modified for critically ill adult SCT recipients. Further, as SCT patients frequently develop severe sepsis, Bernard et al. 68 reported that the use of recombinant human activated protein C administered in a dose of 24 mg/h over 96 h decreased the mortality in a variety of patients who developed this condition. Unfortunately, this study 68 excluded SCT patients and thus it remains to be determined whether this therapy is safe and efficacious in the transplant patient population.
Another important challenge to the SCT clinician is whether earlier involvement of multispecialist management (critical care, pulmonary medicine, infectious disease and nephrology) and transfer of patients to the ICU before the onset of MOSF and other complications will improve patient outcomes. Further, it has not been established whether SCT units equipped to provide critical care management (mechanical ventilation, vasopressor medications) attain superior patient outcomes compared to those programs that rely upon separate ICUs. Also, it is uncertain whether combinations of critical care resource utilization, such as the need for mechanical ventilation and hemodynamic support with pressors and hemodialysis are a predictor of mortality. These and many other unresolved clinical and therapeutic challenges underscore the need for comprehensive, sophisticated strategies to enhance our knowledge of improved, evidence-based treatment paradigms.
Future research could be facilitated by the development of prospective multi-center trials to address many of the unresolved issues. The data we review herein have demonstrated some of the limitations in this literature, including the obvious issue of patient selection bias, for example, which patients undergo transplant and are at-risk for eventual ICU transfer. Identification of effective prognostic factors may contribute intelligent resource allocation. In addition to obvious patient-, disease-and treatment-related variables, there are moral and economic considerations when identifying which patients may benefit from an ICU transfer. Most published trials to date suffer from lack of sufficient populations to answer important questions. SCT recipients comprise a heterogeneous group and larger populations from many centers are needed in order to reduce the biases of retrospective and single-center reports.
